Floatz logo

177lu-psma

68Ga-PSMA PET/CT Positive

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSradiopharmaceuticalPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

513 Active assets in the 68Ga-PSMA PET/CT Positive cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
AVOLVE
Masonic Cancer Center, University of Minnesota
Phase 4BB

View all 50 →

Same molecule, other indications

177lu-psma is also rated in:

Metastatic Castration Resistant Prostate CancerDormant
BB
Indicative ·
67 / 100
View asset →
metastatic prostate carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
castration-resistant prostate carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →